Glycemic variability

At comparable mean glucose and hypoglycemic exposure, fluctuations in glucose cause additional structural injury to human peptidergic C-fibers through nonlinear stress or incomplete recovery.

Scope: Default early type 2 DPN, with a stricter comparison holding mean exposure and hypoglycemic burden comparable. This prices an additional effect of the glucose waveform, not the already established importance of chronic glycemic exposure.

Causal role: temporal modifier of glucose-related injury. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint.

Source assessment

Base judgment: 11.5%; skeptical–optimistic sensitivity: 0.7%–45.4%. Subjective probabilities of the causal proposition below, not effect sizes. Decimal places only show arithmetic. Reviewed 13 September 2026. Probability method · Collection index.

Reasoning from the biological requirements

If instantaneous injury were a linear function of glucose concentration and recovery had no memory, two waveforms with the same integrated glucose exposure would cause the same injury. Variability can add harm only if there is a nonlinear response, a threshold, a harmful recovery process, or a lag that changes the balance of damage and repair. These are alternative ways for the proposition to be true, not four required mechanisms. A coefficient of variation is a summary statistic; it is not a molecule or an independent biological cause.

Probabilities of the necessary claims

Conditional prices are skeptical / base / optimistic. Each price after the first assumes all earlier requirements are true. Their order is an order for assessing joint belief, not necessarily a linear biological pathway. The cumulative column uses the base scenario. Temporal order, connected compartments and the causal prevention comparison are included in these requirements, without extra generic multipliers.

See the claims and probabilities table above.

R1

Blood excursions are real; local buffering and temporal filtering may reduce the fluctuations reaching axons.

R2

Nonlinearity and recovery delays are possible, but average hyperglycemia and low-glucose episodes explain much of the available association.

R3

Cell stress and broader small-fiber correlations leave the exact human structural bridge unproven.

R4

Identifying an independent waveform effect in humans is difficult because treatments change several glucose features together.

Evidence that moves the judgment

• The CGM/corneal study found lower branch density in the higher-variability diabetes group: 25.0 versus 38.6 branches/mm², P=.007. Its small cross-sectional design and four-day exposure record cannot separate a causal waveform effect from hypoglycemia, mean exposure or disease severity. Gad et al., 2022.

• Alternating low and high glucose produced ER stress, oxidative stress and apoptosis in mouse Schwann cells. It supplies a possible temporal-stress mechanism, but does not isolate variability at matched human mean exposure and low-glucose burden. Kato et al., 2019.

Why these odds and how uncertain they are

I put the principal discount on the extra causal effect after matching exposure. A significant association between HbA1c variability and neuropathy would not automatically answer this question: changing treatment, renal function, illness and pre-existing neuropathy can all affect both. Physical plausibility keeps the price above a purely speculative claim, but the human structural evidence is much weaker than evidence for glucose-related injury in general.

The low scenario assumes a nearly exposure-integrating nerve with adequate recovery, so the apparent signal comes from mean glucose, hypoglycemia and illness. The high scenario assumes a threshold or recovery lag makes excursions disproportionately damaging. The range is especially sensitive to how well the comparison holds other features of glucose exposure constant; loosening that requirement would price a different, easier proposition.

Conditional inputs: base [85, 45, 60, 50]%; skeptical [60, 20, 30, 20]%; optimistic [95, 75, 85, 75]%. Products give the headline prices. The span measures sensitivity to these interpretations; it is not a statistical confidence interval.

Numerical update example: A public longitudinal analysis showing a reproducible structural effect of waveform shape after credible matching of mean exposure, low-glucose burden and baseline nerve status would raise requirement 2. A matched analysis in which the waveform effect disappears would lower it. Changing only requirement 2 from 45% to 80% raises the whole price to 20.4%; reducing it to 15% lowers the price to 3.8%. These are hypothetical evidence updates. Even resolving that one requirement with certainty would leave a complete price of 25.5% if the others stayed unchanged.

Overlap and boundary

A modifier of carbonyl stress, ER stress or oxidative injury, not an independent source of molecules. Hypoglycemia is priced separately. Epigenetic persistence concerns a longer-lasting state after exposure changes.